The need for dried plasma – a national issue

Anthony E. Pusateri*, Frank K. Butler, Stacy A. Shackelford, Jason L. Sperry, Ernest E. Moore, Andrew P. Cap, Audra L. Taylor, Mary J. Homer, W. Keith Hoots, Richard B. Weiskopf, Michael R. Davis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Recent studies have demonstrated that early transfusion of plasma or RBCs improves survival in patients with severe trauma and hemorrhagic shock. Time to initiate transfusion is the critical factor. It is essential that transfusion begin in the prehospital environment when transport times are longer than approximately 15 to 20 minutes. Unfortunately, logistic constraints severely limit the use of blood products in the prehospital setting, especially in military, remote civilian, and mass disaster circumstances, where the need can be most acute. US military requirements for logistically supportable blood products are projected to increase dramatically in future conflicts. Although dried plasma products have been available and safely used in a number of countries for over 20 years, there is no dried plasma product commercially available in the United States. A US Food and Drug Administration–approved dried plasma is urgently needed. Considering the US military, disaster preparedness, and remote civilian trauma perspectives, this is an urgent national health care issue.

Original languageEnglish
Pages (from-to)1587-1592
Number of pages6
Issue numberS2
StatePublished - Apr 2019
Externally publishedYes


Dive into the research topics of 'The need for dried plasma – a national issue'. Together they form a unique fingerprint.

Cite this